Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,

Yvonne Hsu, Rima M Saliba, PhD, Grace-Julia Okoroji, Susan o'Brien, Alessandra Ferrajoli, MD, Lynne V. Abruzzo, MD, PhD, Richard Champlin, MD, Michael J Keating, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 4123.

https://doi.org/10.1182/blood.V118.21.4123.4123

Published: 2011

Journal Articles

Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)

Issa F. Khouri, Roland Bassett, Pedro Cano, Susan O'Brien, Yvonne Hsu, Carlos E. Bueso-Ramos, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Alessandra Ferrajoli, Richard Champlin, John McMannis, Marcelo Fernandez-Vina

Blood (2010) 116 (21): 2548.

https://doi.org/10.1182/blood.V116.21.2548.2548

Published: 2010

Journal Articles

Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).

Issa F Khouri, Roland L Bassett, Jr., Pedro Cano, Susan O'Brien, Yvonne Hsu, Carlos E Bueso-Ramos, Robyn Harrell, Grace-Julia Okoroji, Leandro De Padua Silva, Alessandra Ferrajoli, William Wierda, Hagop Kantarjian, Richard Champlin, John McMannis, Marcelo Fernandez-Vina

Blood (2009) 114 (22): 2287.

https://doi.org/10.1182/blood.V114.22.2287.2287

Published: 2009

Journal Articles

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Issa Khouri, Roland L Bassett, Yvonne Hsu, Timothy Dickason, Sandra Acholonu, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Martin J. Korbling, Amin M. Alousi, Chitra Hosing, Uday Popat, Sergio A. Giralt, Partow Kebriaei, Muzaffar H. Qazilbash, M.D., Celina Ledesma, Michael J. Keating, MB, BS, Richard E. Champlin, Carlos Bueso-Ramos

Blood (2008) 112 (11): 1128.

https://doi.org/10.1182/blood.V112.11.1128.1128

Published: 2008

Journal Articles

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).

Issa F Khouri, M.D., Roland Bassett, Barry Samuels, Farzaneh Maadani, Grace-Julia Okoroji, Robyn Harrell, Martin Korbling, Leandro de Padua Silva, Amin Alousi, Chitra Hosing, Sergio Giralt, Marcos de Lima, Paolo Anderlini, Uday Popat, Rosamar Valverde, Yvonne Hsu, Fredrick Hagemeister, Peter McLaughlin, L. Jeffrey Medeiros

Blood (2008) 112 (11): 1140.

https://doi.org/10.1182/blood.V112.11.1140.1140

Published: 2008

Journal Articles

Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission.

Issa F Khouri, Adriana Lopez, Grace-Julia Okoroji, Martin Korbling, MD, Gloria McCormick, Yvonne Hsu, Leandro de Padua, Amin M. Alousi, Chitra M. Hosing, Partow Kebriaei, MD, Gabriela Rondon, Sergio A Giralt, MD, Marcos J. de Lima, Paolo Anderlini, Uday R Popat, Muzaffar H. Qazilbash, Richard E. Champlin, Barbara Pro

Blood (2008) 112 (11): 1141.

https://doi.org/10.1182/blood.V112.11.1141.1141

Published: 2008

Journal Articles

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Blood (2008) 112 (11): 1142.

https://doi.org/10.1182/blood.V112.11.1142.1142

Published: 2008

Journal Articles

Hyperacute GVHD: risk factors, outcomes, and clinical implications

Rima M. Saliba, Marcos de Lima, Sergio Giralt, Borje Andersson, Issa F. Khouri, Chitra Hosing, Shubhra Ghosh, Joyce Neumann, Yvonne Hsu, Jorge De Jesus, Muzaffar H. Qazilbash, Richard E. Champlin, Daniel R. Couriel

Blood (2006) 109 (7): 2751–2758.

https://doi.org/10.1182/blood-2006-07-034348

Published: 2006

Journal Articles

Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin’s Lymphoma.

Rima M. Saliba, PhD, Issa F. Khouri, MD, Marcos de Lima, MD, Chitra Hosing, MD, Grace Okoroji, MS, Sandra Acholonou, MS, Farzaneh Maadani, MS, Jorge De Jesus, RN, Yvonne Hsu, PA, Richard E. Champlin, MD, Daniel R. Couriel, MD

Blood (2006) 108 (11): 5316.

https://doi.org/10.1182/blood.V108.11.5316.5316

Published: 2006

Journal Articles

Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD

Daniel R. Couriel, Chitra Hosing, Rima Saliba, Elizabeth J. Shpall, Paolo Anderlini, Beverly Rhodes, Veronica Smith, Issa Khouri, Sergio Giralt, Marcos de Lima, Yvonne Hsu, Shubhra Ghosh, Joyce Neumann, Borje Andersson, Muzzafar Qazilbash, Sharon Hymes, Stella Kim, Richard Champlin, Michele Donato

Blood (2006) 107 (8): 3074–3080.

https://doi.org/10.1182/blood-2005-09-3907

Published: 2006

Journal Articles

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Chitra Hosing, MD, Rima M. Saliba, PhD, Marcos De Lima, MD, Sergio Giralt, MD, Shubhra Ghosh, MD, Yvonne Hsu, Paolo Anderlini, MD, Sharon R. Hymes, MD, Borje Andersson, MD, Issa F. Khouri, MD, Richard Champlin, MD, Daniel Couriel, MD

Blood (2005) 106 (11): 1123.

https://doi.org/10.1182/blood.V106.11.1123.1123

Published: 2005

Journal Articles

The Clinical Spectrum of Acute GVHD: Beyond Day 100.

Daniel R. Couriel, MD, Rima Saliba, PhD, Shubhra Gosh, MD, Marcos De Lima, MD, Sergio Giralt, MD, Issa Khouri, MD, Borje Andersson, MD, Kerry Mickler, RN, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, RN, APN, Sharon Hymes, MD, Stella Kim, MD, Richard Champlin, MD

Blood (2005) 106 (11): 5377.

https://doi.org/10.1182/blood.V106.11.5377.5377

Published: 2005

Journal Articles

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Rima M. Saliba, PhD, Marcos de Lima, MD, Chitra Hosing, MD, Issa F. Khouri, MD, Sergio Giralt, MD, Paolo Anderlini, MD, Shubhra Ghosh, MD, Kerry Mickler, RN, Cindy Ippoliti, PHARMD, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, APN, Richard Champlin, MD, Daniel R. Couriel, MD

Blood (2005) 106 (11): 1799.

https://doi.org/10.1182/blood.V106.11.1799.1799

Published: 2005

Journal Articles

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Daniel R. Couriel, MD, Peter Thall, PhD, Kerry Mickler, RN, Marcos De Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Chitra Hosing, MD, Issa Khouri, MD, Partow Kebriaei, MD, Yvonne Hsu, MD, Rima Saliba, MD, Cindy Ippoliti, PharmD, Richard Champlin, MD

Blood (2005) 106 (11): 142.

https://doi.org/10.1182/blood.V106.11.142.142

Published: 2005

Journal Articles

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Daniel R. Couriel, MD, Rima Saliba, PhD, Marcos J. de Lima, MD, Chitra Hosing, MD, Borje Andersson, MD, Jorge De Jesus, RN, Kerry Mickler, RN, Yvonne Hsu, PA, Elizabeth J. Shpall, MD, Shubhra Ghosh, MD, Richard Champlin, MD

Blood (2004) 104 (11): 734.

https://doi.org/10.1182/blood.V104.11.734.734

Published: 2004

NARROW

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,

Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)

Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).

Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission.

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Hyperacute GVHD: risk factors, outcomes, and clinical implications

Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin’s Lymphoma.

Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

The Clinical Spectrum of Acute GVHD: Beyond Day 100.

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only